Domov › Mikrocitni rak pljuč › Massachusetts › Boston
Klinične študije za Mikrocitni rak pljuč v Boston, MA
21 študij za Mikrocitni rak pljuč išče udeležence na lokacijah v Boston in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
Vključevanje udeležencevFaza 2
- Dana-Farber Cancer Institute /ID# 277732, Boston
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Vključevanje udeležencevFaza 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Vključevanje udeležencevFaza 1
- Dana Farber Cancer Institute, Boston
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Vključevanje udeležencevFaza 1/2
- Tufts Medical Center, Boston
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
Vključevanje udeležencevFaza 3
- Dana-Farber Cancer Institute /ID# 279690, Boston
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Vključevanje udeležencevFaza 1
- Massachusetts General Hospital, Boston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Vključevanje udeležencevFaza 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
Vključevanje udeležencevFaza 1/2
- Dana Farber Cancer Institute ( Site 1105), Boston
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Vključevanje udeležencevFaza 1/2
- Avenzo Therapeutics Recruiting Site, Boston
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- Dana Farber Cancer Institute, Boston
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
Vključevanje udeležencevFaza 2
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- Massachusetts General Hospital Cancer Center, Boston
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Vključevanje udeležencevFaza 3
- Dana-Farber Cancer Institute, Boston
Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
Vključevanje udeležencevFaza 1
- Massachusetts General Hospital, Boston
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- Beth Israel Deaconess Medical Center, Boston
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Vključevanje udeležencevFaza 1/2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
Vključevanje udeležencevFaza 2
- Dana Farber Cancer Institute, Boston
A Study of LY4175408 in Participants With Advanced Cancer
Vključevanje udeležencevFaza 1
- Massachusetts General Hospital, Boston
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
Vključevanje udeležencevFaza 2
- Tufts Medical Center, Boston
Biology of Young Lung Cancer Study: The YOUNG LUNG Study
Vključevanje udeležencevOpazovalna študija
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Brigham and Women's Hospital, Boston
- in še 1
DNA Analysis of Blood and Tissue from Patients with Lung Cancer
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
- Massachusetts General Hospital, Boston
- Harvard School of Public Health, Boston
Študije za Mikrocitni rak pljuč v drugih mestih
- Houston, TX26 študij
- Arlington, VA23 študij
- New York City, NY21 študij
- Nashville, TN20 študij
- Los Angeles, CA20 študij
- Orlando, FL15 študij
- Dallas, TX13 študij
- St. Louis, MO13 študij
- Cleveland, OH13 študij
- Detroit, MI12 študij
- Chicago, IL12 študij
- Washington, DC12 študij
Druge študije v Boston
- Rak dojke111 študij
- Nemalicelični pljučni rak90 študij
- Rak (vse vrste)86 študij
- Kolorektalni rak63 študij
- Metastatski rak63 študij
- Rak pljuč62 študij
- Rak jajčnikov61 študij
- Rak prostate59 študij
- Depresija52 študij
- Rak endometrija50 študij
- Srčno popuščanje44 študij
- Akutna mieločna levkemija44 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.